2020
Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
Higgins AY, Annapureddy AR, Wang Y, Minges KE, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy. Journal Of The American Heart Association 2020, 9: e016038. PMID: 32867553, PMCID: PMC7726970, DOI: 10.1161/jaha.120.016038.Peer-Reviewed Original ResearchConceptsImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationNonischemic cardiomyopathyCardiac amyloidosisDiabetes mellitusCerebrovascular diseaseVentricular tachycardiaMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesCox proportional hazards modelPropensity-matched cohortOutcomes of patientsHazards regression modelsProportional hazards modelCause mortalityICD implantationRenal functionMultivariable analysisConclusions MortalityRisk factorsRegistry dataAmyloid cardiomyopathyHigh risk
2019
Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement
Strom JB, Zhao Y, Faridi KF, Tamez H, Butala NM, Valsdottir LR, Curtis J, Brennan JM, Shen C, Boulware M, Popma JJ, Yeh RW. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation Cardiovascular Interventions 2019, 12: e008231. PMID: 31694411, PMCID: PMC7212938, DOI: 10.1161/circinterventions.119.008231.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic ValveAortic Valve StenosisBrain IschemiaClinical Trials as TopicDatabases, FactualFemaleHeart Valve Prosthesis ImplantationHumansIschemic Attack, TransientMaleMedicareRisk AssessmentRisk FactorsStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsNegative predictive valueAortic valve replacementCerebrovascular eventsInternational ClassificationPositive predictive valuePredictive valueValve replacementNinth RevisionClinical trialsTenth RevisionBilling codesKaplan-Meier estimatesMedicare inpatient claimsSURTAVI trialClinical event adjudicationDevastating complicationIschemic strokeNeurological eventsCerebrovascular diseaseBilling claimsInpatient claimsEvent adjudicationAdministrative claimsHigh riskTrial participants
2014
Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants
Prutkin JM, Reynolds MR, Bao H, Curtis JP, Al-Khatib SM, Aggarwal S, Uslan DZ. Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants. Circulation 2014, 130: 1037-1043. PMID: 25081281, DOI: 10.1161/circulationaha.114.009081.Peer-Reviewed Original ResearchConceptsICD infectionImplantable cardioverter defibrillator implantImplantable cardioverter-defibrillator infectionIndirect patient identifiersPrevious valve surgeryPrevious valvular surgeryChronic lung diseaseCardioverter-defibrillator implantICD-9 codesService claims dataCardioverter-defibrillator infectionComorbidity burdenManufacturers' advisoriesValvular surgeryEarly reinterventionValve surgeryAdverse eventsHospital dischargeRenal failureICD RegistryCerebrovascular diseaseImplant complicationsLung diseaseBiventricular ICDsMedicare patients
2010
Acute Lead Dislodgements and In-Hospital Mortality in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry
Cheng A, Wang Y, Curtis JP, Varosy PD. Acute Lead Dislodgements and In-Hospital Mortality in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. Journal Of The American College Of Cardiology 2010, 56: 1651-1656. PMID: 21050975, DOI: 10.1016/j.jacc.2010.06.037.Peer-Reviewed Original ResearchConceptsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryImplantable Cardioverter-Defibrillator RegistryLead dislodgementAcute dislodgementHospital deathAdverse eventsNew York Heart Association functional class IV heart failureAtrial fibrillation/flutterCardiac resynchronization therapy-defibrillator deviceClass IV heart failureCommon adverse eventsIn-Hospital MortalityLow ejection fractionChronic lung diseaseMore comorbiditiesCardiac tamponadeMultivariate adjustmentEjection fractionHeart failureNonischemic cardiomyopathyAtrial fibrillationCerebrovascular diseaseCardiac arrestLung diseasePotential confounders
2004
Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke
Sokol SI, Portnay EL, Curtis JP, Nelson MA, Hebert PR, Setaro JF, Foody JM. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004, 63: 208-213. PMID: 15277610, DOI: 10.1212/01.wnl.0000130360.21618.d0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsAnimalsBrainChronic DiseaseDouble-Blind MethodDrug Evaluation, PreclinicalEndothelium, VascularFibrinolysisHemostasisHumansInflammationMiddle AgedNerve RegenerationRandomized Controlled Trials as TopicRatsReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Renin-Angiotensin SystemSecondary PreventionStrokeTreatment OutcomeConceptsRenin angiotensin aldosterone systemRAAS modulationRecurrent strokeAldosterone systemCerebrovascular eventsStroke preventionSecondary preventionACE inhibitorsCerebrovascular diseaseAngiotensin II type 1 receptor blocker therapiesBlood pressure-independent mechanismsMajor public health concernReceptor blocker therapyRecurrent cerebrovascular eventsRecurrent stroke preventionAngiotensin aldosterone systemBlood pressure reductionSecondary stroke preventionRecurrent cardiac eventsPressure-independent mechanismsVascular structural changesOngoing clinical trialsNew treatment strategiesPublic health concernBlocker therapy